755030-94-5

Upstream product

• 677777-44-5 4-iodo-2-methoxybenzonitrile 
• 73183-34-3 bis(pinacol)diborane 
• 330793-38-9 4-bromo-2-methoxybenzonitrile 
• 1350933-21-9 2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 
• 74-88-4 methyl iodide 

Downstream Products

• 1308669-02-4 (S)-2-methoxy-4-[5-fluoro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-benzonitrile 
• 1308669-01-3 (R)-2-methoxy-4-[5-fluoro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-benzonitrile 
• 1308669-00-2 2-methoxy-4-[5-fluoro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-benzonitrile 
• 1308669-28-4 (S)-4-[5-chloro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308669-25-1 (R)-4-[5-chloro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308669-24-0 4-[5-chloro-4-(1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308668-80-5 4-[4-(1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308668-83-8 4-[4-((S)-1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308668-81-6 4-[4-((R)-1-hydroxy-ethyl)-pyridin-3-yl]-2-methoxy-benzonitrile 
• 1308670-06-5 4-(4-formylpyridin-3-yl)-2-methoxybenzonitrile 

Relevant academic research and scientific papers

N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation,

ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are defined herein. The invention also relates to a method for manufacturing compounds of the invention, and their therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS

The present invention provides a compound of Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Compounds of formula A: Formula (1) pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by Raf kinases.

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.